Statistiques de base
| LEI | 549300QZYQDSMOXCP667 |
| CIK | 1259942 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BELLUS Health Inc.
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| August 14, 2023 |
BLU / Bellus Health Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) August 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39034 BELLUS HEALTH INC. (Exact name of registrant as specified in its c |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execu |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration Nos. |
|
| June 28, 2023 |
Exhibit 99.1 Stock-exchange announcement For media and investors only Issued: 28 June 2023, London UK GSK completes acquisition of BELLUS Health GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a pl |
|
| June 28, 2023 |
Exhibit 99.1 form 51-102F3 MATERIAL CHANGE REPORT Section 7.1 of National Instrument 51-102 Continuous Disclosure Obligations Item 1: Name and Address of Company BELLUS Health Inc. (“BELLUS Health”) 275 Blvd. Armand-Frappier Laval (Québec) H7V 4A7 Item 2: Date of Material Change June 28, 2023 Item 3: News Release On Wednesday, June 28, 2023, a news release relating to the material change referred |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration Nos. |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execu |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration Nos. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execu |
|
| June 16, 2023 |
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders EX-99.1 2 tm2318826d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders MONTREAL, June 16, 2023 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced the positive outcome of the BELLUS shareholders (“Shareholders”) vote at this morning’s special meeting of the Shareholders (the “Special Meeting |
|
| June 16, 2023 |
Exhibit 99.2 BELLUS HEALTH INC. (the “Company”) REPORT OF VOTING RESULTS Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations Following the Special Meeting of shareholders of the Company held on June 16, 2023 (the “Meeting”), this report discloses the matters voted upon at the Meeting. Reference is made to the management information circular of the Company dated May 16, 2 |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execu |
|
| June 6, 2023 |
Exhibit 99.2 Security Class Holder Account Number Form of Proxy - Annual and Special Meeting to be held on June 30, 2023 at 11:30 am This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, to attend and act on their behalf at the meeting or any adjournment or post |
|
| June 6, 2023 |
BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual and special meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “Company”) will be held in person at 275 Armand Frappier Blvd., Laval, Québec, H7V 4A7 on June 30, 2023 at 11:30 a.m., Montréal time, for the following purposes: (i) to receive and consi |
|
| June 2, 2023 |
Exhibit 99.1 BELLUS HEALTH INC. NOTICE AND AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 May 31, 2023 BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual and special meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “Com |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execu |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal execut |
|
| May 19, 2023 |
Exhibit 99.2 0 BELLUS HEALTH INC. SPECIAL MEETING FRIDAY, JUNE 16, 2023 AT 11:30 A.M. EDT **ISSUER COPY ** FOR HOLDERS AS OF MAY 15, 2023 07987C204 1-800-454-8683 * ISSUER CONFIRMATION COPY - INFO ONLY * JUNE 14, 2023 1 To consider and, if deemed advisable, to pass, with or without RECOMMENDATION: FOR variation, a special resolution to approve a proposed plan of arrangement involving BELLUS Health |
|
| May 19, 2023 |
Exhibit 99.3 THIS LETTER OF TRANSMITTAL IS FOR USE IN CONNECTION WITH THE PLAN OF ARRANGEMENT INVOLVING BELLUS HEALTH INC. THE CIRCULAR AND INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. THIS LETTER OF TRANSMITTAL MUST BE VALIDLY COMPLETED, DULY EXECUTED AND RETURNED TO THE DEPOSITARY, COMPUTERSHARE INVESTOR SERVICES IN |
|
| May 19, 2023 |
TABLE OF CONTENTS Exhibit 99.1 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS to be held on June 16, 2023 and MANAGEMENT INFORMATION CIRCULAR with respect to a plan of arrangement involving GSK PLC and 14934792 CANADA INC. and BELLUS HEALTH INC. RECOMMENDATION TO SHAREHOLDERS: THE BOARD OF DIRECTORS OF BELLUS HEALTH INC. UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE FOR THE ARRANGEMENT RESOLUTION May |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 16, 2023 |
Exhibit 99.1 BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition Special Meeting to be held on June 16, 2023 MONTREAL, May 16, 2023 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“BELLUS” or the “Company”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the “Spec |
|
| May 12, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended March 31, 2023. 2. No mi |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 12, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended March 31, 2023. 2. No misrepresentations: Based on my knowledg |
|
| May 12, 2023 |
Weighted average exercise price (1) Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended March 31, 2023 and 2022 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended March 31, 2023 and 2022 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Condensed |
|
| May 12, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) provides a review of BELLUS Health Inc.’s operations and financial performance for the three-month period ended March 31, 2023. In this MD&A, unless the context otherwise requires, the terms “BELLUS Health”, “Company”, “we”, “us”, and “our” refer to BELLUS Health Inc. This document should be read i |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 12, 2023 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close in Q3 |
|
| April 28, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - BELLUS Health Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. L |
|
| April 28, 2023 |
EX-99.1 2 exhibit99-1.htm NOTICE OF THE MEETING AND RECORD DATE Exhibit 99.1 Date: April 28, 2023 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 CANCELLED www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting |
|
| April 28, 2023 |
Exhibit 99.1 Exhibit 99.1 Date: April 28, 2023 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual Meeting Record Date for Notice of Meeting : May |
|
| April 28, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - BELLUS Health Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. L |
|
| April 27, 2023 |
BELLUS Health Announces Meeting Updates Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Meeting Updates LAVAL, Quebec-(BUSINESS WIRE)-April 26, 2023-BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of c |
|
| April 27, 2023 |
GSK PLC, 14934792 CANADA INC., BELLUS HEALTH INC. ARRANGEMENT AGREEMENT April 17, 2023 Exhibit 99.2 EXECUTION VERSION GSK PLC, 14934792 CANADA INC., and BELLUS HEALTH INC. ARRANGEMENT AGREEMENT April 17, 2023 ARTICLE I INTERPRETATIONS 1 Section 1.1 Defined Terms 1 Section 1.2 Certain Rules of Interpretation 19 Section 1.3 Company Disclosure Schedule 20 ARTICLE II THE ARRANGEMENT 20 Section 2.1 Arrangement 20 Section 2.2 Interim Order 20 Section 2.3 The Company Meeting 21 Section 2.4 |
|
| April 27, 2023 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company BELLUS Health Inc. (“BELLUS Health”) 275 Blvd. Armand-Frappier Laval (Québec) H7V 4A7 Item 2 Date of Material Change April 17, 2023 Item 3 News Release A news release was issued on April 18, 2023, and disseminated by Business Wire, a copy of which has been filed and is available on the SEC website at www.sec.gov a |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 27, 2023 |
D&O SUPPORT AND VOTING AGREEMENT Exhibit 99.3 D&O SUPPORT AND VOTING AGREEMENT April 17, 2023 14934792 CANADA INC. 980 Great West Road Brentford, Middlesex, United Kingdom GSK PLC 980 Great West Road Brentford, Middlesex, United Kingdom Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that 14934792 CANADA INC. (the “Purchaser”), GSK PLC (the “Parent”) and BELLUS HEALTH INC. (the “Company”) wish to en |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal exec |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 25, 2023 |
EX-99.1 2 exhibit99-1.htm NOTICE OF THE MEETING AND RECORD DATE Exhibit 99.1 Date: April 24, 2023 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Spe |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant’s name into English) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal exec |
|
| April 18, 2023 |
Exhibit 99.1 Stock-exchange announcement For media and investors only Issued: 18 April 2023, London UK GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health · Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough · Currently in |
|
| April 5, 2023 |
EX-99.1 2 a53375596ex991.htm EXHIBIT 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation Once-daily Extended-Release formulation demonstrated equivalent bi |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 30, 2023 |
Exhibit 99.3 |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 30, 2023 |
BLU / Bellus Health Inc / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2023 |
Exhibit 99.4 |
|
| March 30, 2023 |
Exhibit 99.2 Exhibit 99.2 BELLUS HEALTH INC. NOTICE AND MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON MAY 4, 2023 MARCH 21, 2023 BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual and special meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “Company”) w |
|
| March 30, 2023 |
BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 Exhibit 99.1 BELLUS HEALTH INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual and special meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “Company”) will be held in person at 275 Armand Frappier Blvd., Laval, Québec, H7V 4A7 on May 4, 2023 at 11:30 a.m., Montréal time, for the following purposes: (i) to receiv |
|
| March 29, 2023 |
Weighted average exercise price (1) Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) provides a review of BELLUS Health Inc.’s operations and financial performance for the years ended December 31, 2022 and 2021. In this MD&A, unless the context otherwise requires, the terms “BELLUS Health”, “we”, “us”, and “our” refer to BELLUS Health Inc. This document should be read in conjunctio |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 23, 2023 |
Consent of Independent Registered Public Accounting Firm – KPMG LLP Exhibit 99.8 KPMG LLP 600 de Maisonneuve Blvd West Suite 1500, Tour KPMG Montréal (Québec) H3A 0A3 Tel. 514-840-2100 Fax. 514-840-2187 www.kpmg.ca CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors BELLUS Health Inc. We consent to the incorporation by reference in the Registration Statement (No. 333-267106) on Form F-10 and (No. 333-233922, 333-238274 and 333-264375 |
|
| March 23, 2023 |
Management’s Discussion and Analysis of the Registrant for the year ended December 31, 2022 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) provides a review of BELLUS Health Inc.’s operations and financial performance for the years ended December 31, 2022 and 2021. In this MD&A, unless the context otherwise requires, the terms “BELLUS Health”, “we”, “us”, and “our” refer to BELLUS Health Inc. This document should be read in conjunctio |
|
| March 23, 2023 |
Exhibit 99.5 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ramzi Benamar, certify that: 1. I have reviewed this annual report on Form 40-F of BELLUS Health Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F (Check One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Exact name of Registrant as |
|
| March 23, 2023 |
Table of Contents Exhibit 99.2 Consolidated Financial Statements of BELLUS HEALTH INC. Years ended December 31, 2022 and 2021 (In thousands of United States dollars) Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of BELLUS Health Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated |
|
| March 23, 2023 |
Exhibit 99.7 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as Chief Financial Officer of BELLUS Health Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2022, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as applicable, |
|
| March 23, 2023 |
Annual Information Form of the Registrant for the year ended December 31, 2022 Table of Contents Exhibit 99.1 BELLUS HEALTH INC. ANNUAL INFORMATION FORM Fiscal year ended December 31, 2022 March 23, 2023 Table of Contents TABLE OF CONTENTS FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 4 NAME, ADDRESS AND INCORPORATION 4 INTERCORPORATE RELATIONSHIPS 4 BUSINESS 4 OVERVIEW 4 HIGHLIGHTS 5 OUR STRATEGY 7 OUR PIPELINE 8 INTELLECTUAL PROPERTY 23 ACQUISITION OF ALL BLU-5937 INTEL |
|
| March 23, 2023 |
Exhibit 99.4 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Roberto Bellini, certify that: 1. I have reviewed this annual report on Form 40-F of BELLUS Health Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whic |
|
| March 23, 2023 |
EX-99.6 7 blu-20221231xex99d6.htm EX-99.6 Exhibit 99.6 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the President and Chief Executive Officer of BELLUS Health Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2022, which accompanies this certification, fully complies wit |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 21, 2023 |
Investor Presentation NASDAQ/TSX - BLU March 21 st , 2023 Exhibit 99.1 Investor Presentation NASDAQ/TSX - BLU March 21 st , 2023 Forward Looking Statements 2 Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the dat e h ereof, may constitute "forward - looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform |
|
| March 21, 2023 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Year 2022 Financial Results and Business Highlights - Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024- - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 1, 2023 |
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference LAVAL, Quebec – March 1, 2023 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) |
|
| February 24, 2023 |
6-K 1 bellushealth6knomrd.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF FEBRUARY 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand- |
|
| February 24, 2023 |
Exhibit 99.1 Exhibit 99.1 Date: February 24, 2023 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for |
|
| February 14, 2023 |
BLU / Blue Chip Value Fund, Inc. / RTW INVESTMENTS, LP - BELLUS HEALTH INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* BELLUS Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2023 |
BLU / Blue Chip Value Fund, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* BELLUS Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2023 |
BLU / Blue Chip Value Fund, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d427581dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2023 |
BLU / Blue Chip Value Fund, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm234574-4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* BELLUS Health Inc. (Name of Issuer) Common Shares without par value (the “Shares”) (Title of Class |
|
| February 14, 2023 |
BLU / Blue Chip Value Fund, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d21sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2023 |
EX-99.1 2 d427581dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 13, 2023 |
BLU / Blue Chip Value Fund, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) BELLUS Health Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 8, 2023 |
EX-99.1 2 a53310139ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting LAVAL, Quebec - February 8, 2023 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Comp |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| February 3, 2023 |
BLU / Blue Chip Value Fund, Inc. / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bellus Health Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 07987C204 (CUSIP Number) 12/31/2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 23, 2023 |
EXHIBIT 1 JOINT FILING STATEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of this Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, no par value, of Bellus Health Inc. |
|
| January 23, 2023 |
BLU / Blue Chip Value Fund, Inc. / Power Corp of Canada Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bellus Health Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 14, 2022 |
TABLE OF CONTENTS No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. |
|
| November 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Based on my know |
|
| November 14, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: |
|
| November 14, 2022 |
Weighted average exercise price (1) Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended September 30, 2022 and 2021 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended September 30, 2022 and 2021 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Co |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant's name into English) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal e |
|
| November 14, 2022 |
As per 2021 and 2022 Prospectus Supplements without options to purchase additional common shares Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three- and nine-month periods ended September 30, 2022. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document s |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Translation of registrant?s name into English) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal e |
|
| November 14, 2022 |
EX-99.1 2 tm2230404d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OPEN MARKET SALE AGREEMENTSM November 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: BELLUS Health Inc. (the “Company”), a company incorporated under the Canada Business Corporations Act (the “CBCA”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time th |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| November 14, 2022 |
EX-99.1 2 a52969044ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights - Initiated CALM Phase 3 program with topline data expected for CALM-1 and CALM-2 in the second half of 2024 and 2025, respectively - - Ended third quarter 2022 with US$364.4 million in c |
|
| November 10, 2022 |
6-K 1 a52966664.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Addres |
|
| November 10, 2022 |
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences LAVAL, Quebec ? November 10, 2022 ? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (?R |
|
| October 11, 2022 |
EX-99.1 2 a52939858ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting LAVAL, Quebec – October 10, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developin |
|
| October 11, 2022 |
6-K 1 a52939858.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address |
|
| September 16, 2022 |
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022 Exhibit 99.1 Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022 Forward Looking Statements 2 Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the dat e h ereof, may constitute "forward - looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Ref |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| September 6, 2022 |
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference EX-99.1 2 a52854254ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present at the H.C. Wainwright Global Investment Conference LAVAL, Quebec – September 6, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| August 26, 2022 |
Form F-10 (File No. 333-267106) F-10 1 tm2224501-1f10.htm F-10 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BELLUS HEALTH INC. (Exact Name of Registrant as Specified In Its Charter) Not applicable (Translation of Registran |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): BELLUS Health Inc. B. (1) This is: x an original filing for the Filer. ¨ an amended filing for the Filer. (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S- T Rule |
|
| August 26, 2022 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing fee tables Form F-10 (Form Type) BELLUS HEALTH INC. |
|
| August 22, 2022 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 Bellus Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022 LAVAL, Quebec – August 22, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| August 10, 2022 |
Weighted average exercise price (1) Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended June 30, 2022 and 2021 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended June 30, 2022 and 2021 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Condensed Co |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| August 10, 2022 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three and six-month periods ended June 30, 2022. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document should b |
|
| August 10, 2022 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights - Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (?FDA?) and received scientific advice from the European Medicines Agency (?EMA?) to support design of its CALM Phase 3 program, which is expected |
|
| August 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| August 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based on my knowledge |
|
| July 18, 2022 |
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States EX-99.1 2 tm2221255d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States LAVAL, Quebec, July 18, 2022 – BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Of |
|
| July 18, 2022 |
6-K 1 tm2221255d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal |
|
| July 15, 2022 |
TABLE OF CONTENTS Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-261632 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. A registration statement related to these securities has been filed with the United States Securities and Exchange Commission and has been declared effective. This prospectus supp |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by c |
|
| July 14, 2022 |
16,540,541 Common Shares BELLUS Health Inc. UNDERWRITING AGREEMENT Exhibit 99.2 16,540,541 Common Shares BELLUS Health Inc. UNDERWRITING AGREEMENT July 13, 2022 JEFFERIES LLC EVERCORE GROUP L.L.C. RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street, 35th Floor New York, New York 10055 c/o RBC CAPITAL MARKETS, LLC Brookfield Place 200 Ves |
|
| July 14, 2022 |
EX-99.1 2 tm2220974d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States Common Shares Priced at US$9.25 per Share LAVAL, Quebec, July 13, 2022 – In connection with its previously announced public offering of common shares in Canada and the U |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by c |
|
| July 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by c |
|
| July 13, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to General Instruction II.L. of Form F-10? ?File No. 333-261632? No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. A copy of this preliminary prospectus supplement has been filed with the securities regulatory authorities in each of the provinces of Canada but has not yet become final for th |
|
| July 13, 2022 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States LAVAL, Quebec, July 13, 2022 ? BELLUS Health Inc. (?BELLUS Health? or the ?Company?) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the ?Supplement?) to its amended |
|
| July 13, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company BELLUS Health Inc. (?BELLUS Health? or the ?Company?) 275 Blvd. Armand-Frappier Laval (Qu?bec) H7V 4A7 Item 2 Date of Material Change July 12, 2022 Item 3 News Release A news release was issued on July 12, 2022, and disseminated by Business Wire, in Canada and in the United States. Item 4 Summary of Material Chang |
|
| July 12, 2022 |
Exhibit 99.1 Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough - CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively - - The Company has reached alignment with FDA on the primary efficacy e |
|
| July 12, 2022 |
Exhibit 99.2 BLU - 5937 for Refractory Chronic Cough: Positive FDA End of Phase 2 Meeting and its CALM Phase 3 Program Design JULY 12, 2022 Forward Looking Statements 1 Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the dat e h ereof, may constitute "forward - looking statements" within the meaning of Canadian securities legisl |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate by c |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by c |
|
| July 5, 2022 |
BELLUS Health to Participate in the William Blair Biotech Focus Conference EX-99.1 2 a52768767ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the William Blair Biotech Focus Conference LAVAL, Quebec – July 5, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm |
|
| June 1, 2022 |
6-K 1 a52735974.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of |
|
| June 1, 2022 |
BELLUS Health to Participate in the Jefferies Healthcare Conference Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the Jefferies Healthcare Conference LAVAL, Quebec ? June 1, 2022 ? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (?RCC?) and other |
|
| May 11, 2022 |
Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended March 31, 2022 and 2021 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended March 31, 2022 and 2021 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Condensed |
|
| May 11, 2022 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights - End-of-Phase 2 meeting with the U.S. Food and Drug Administration (?FDA?) scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data fro |
|
| May 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations: Based on my knowledg |
|
| May 11, 2022 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three-month period ended March 31, 2022. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document should be read i |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 11, 2022 |
BELLUS HEALTH INC. (the “Company”) REPORT OF VOTING RESULTS Exhibit 99.3 BELLUS HEALTH INC. (the ?Company?) REPORT OF VOTING RESULTS Following the annual meeting of shareholders of the Company held on May 11, 2022 (the ?Meeting?), this report discloses the matters voted upon at the Meeting. Reference is made to the management information circular of the Company dated March 23, 2022 (the ?Circular?). Election of Directors On a vote by ballot, the following |
|
| May 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 tm2214905d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended M |
|
| May 11, 2022 |
6-K 1 a52716615.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of |
|
| May 2, 2022 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference LAVAL, Quebec ? May 2, 2022 ? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-stage biopharmaceutical company developing novel therapeu |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| April 25, 2022 |
BELLUS Health to Participate in Multiple Upcoming Investor Conferences Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in Multiple Upcoming Investor Conferences LAVAL, Quebec ? April 25, 2022 ? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (?RCC?) and |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 19, 2022 |
As filed with the Securities and Exchange Commission on April 19, 2022 As filed with the Securities and Exchange Commission on April 19, 2022 Registration No. |
|
| April 19, 2022 |
As filed with the Securities and Exchange Commission on April 19, 2022 S-8 POS 1 tm2212459d3s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on April 19, 2022 Registration No. 333-233922 Registration No. 333-238274 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement (No. 333-233922) Post-Effective Amendment No. 1 to Form S-8 Registration Statement (No. 333-2382 |
|
| April 19, 2022 |
As filed with the Securities and Exchange Commission on April 19, 2022 As filed with the Securities and Exchange Commission on April 19, 2022 Registration No. |
|
| April 19, 2022 |
Amended Stock Option Plan (effective February 23, 2022) EX-4.1 2 tm2212459d2ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Stock Option Plan 1 PURPOSE OF PLAN 1.1 The purpose of the Plan is to assist directors, officers, key employees, consultants and members of the Clinical Advisory Board (if any) of the Corporate Group to participate in the growth and development of the Corporate Group by providing such persons with the opportunity, through share options, to acqu |
|
| April 19, 2022 |
Amended Stock Option Plan (effective February 23, 2022) EX-4.1 2 tm2212459d3ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Stock Option Plan 1 PURPOSE OF PLAN 1.1 The purpose of the Plan is to assist directors, officers, key employees, consultants and members of the Clinical Advisory Board (if any) of the Corporate Group to participate in the growth and development of the Corporate Group by providing such persons with the opportunity, through share options, to acqu |
|
| April 19, 2022 |
EX-FILING FEES 4 tm2212459d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BELLUS Health Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common |
|
| April 7, 2022 |
Exhibit 99.4 |
|
| April 7, 2022 |
Exhibit 99.5 Exhibit 99.5 |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 7, 2022 |
EX-99.3 4 exhibit99-3.htm FORM OF PROXY Exhibit 99.3 |
|
| April 7, 2022 |
BELLUS HEALTH INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS EX-99.1 2 exhibit99-1.htm NOTICE OF THE MEETING Exhibit 99.1 BELLUS HEALTH INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “Company”) will be held via live webcast at https://meetnow.global/MMST9PV, on May 11, 2022 at 2:30 p.m., Montréal time, for the following purposes: (i) to receiv |
|
| April 7, 2022 |
EX-99.2 3 exhibit99-2.htm MANAGEMENT INFORMATION CIRCULAR Exhibit 99.2 BELLUS HEALTH INC. NOTICE AND MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON MAY 11, 2022 MARCH 23, 2022 BELLUS HEALTH INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual meeting (the “Meeting”) of the common shareholders of BELLUS Health Inc. (the “C |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 5, 2022 |
All patients — Intent to Treat Patient Population (n=67) EX-99.1 2 tm2211385d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) provides a review of BELLUS Health Inc.’s operations and financial performance for the years ended December 31, 2021 and 2020. In this MD&A, unless the context otherwise requires, the terms “BELLUS Health”, “we”, “us”, and “our” refer to BELLUS Health In |
|
| March 4, 2022 |
EX-99.1 2 exhibit99-1.htm NOTICE OF MEETING AND RECORD DATE Exhibit 99.1 Date: March 04, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: BELLUS HEALTH INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| March 1, 2022 |
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference LAVAL, Quebec – Mar. 1, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“ |
|
| February 23, 2022 |
EX-99.1 2 a52584574ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Year 2021 Financial Results and Business Highlights - Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to r |
|
| February 23, 2022 |
Exhibit 99.7 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as Chief Financial Officer of BELLUS Health Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2021, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as applicable, |
|
| February 23, 2022 |
Consent of Independent Registered Public Accounting Firm – KPMG LLP Exhibit 99.8 ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ? To the Board of Directors of BELLUS Health Inc. ? We consent to the incorporation by reference in the Registration Statement (No. 333-261632 and 333-251329) on Form F-10 and (No. 333-233922 and 333-238274) on Forms S-8 of BELLUS Health Inc. of our report dated February 23, 2022, on the consolidated financial statements, whic |
|
| February 23, 2022 |
Table of Contents Exhibit 99.2 Consolidated Financial Statements of BELLUS HEALTH INC. Years ended December 31, 2021 and 2020 (In thousands of United States dollars) Table of Contents KPMG LLP Telephone (514) 840-2100 600 de Maisonneuve Blvd., West Fax (514) 840-2187 Suite 1500 Internet www.kpmg.ca Tour KPMG Montréal (Québec) H3A 0A3 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the S |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 40-F ? (Check One) ? ? REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? OR ? ? ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended: December 31, 2021 Commission File Number: 001-39034 ? BELLUS HEALTH INC. (Exact name |
|
| February 23, 2022 |
our annual information form dated February 23, 2022 for the fiscal year ended December 31, EX-99.1 2 blu-20211231xex99d1.htm EX-99.1 Table of Contents Exhibit 99.1 BELLUS HEALTH INC. ANNUAL INFORMATION FORM Fiscal year ended December 31, 2021 February 23, 2022 Table of Contents TABLE OF CONTENTS FORWARD-LOOKING STATEMENTS 1 CORPORATE STRUCTURE 4 NAME, ADDRESS AND INCORPORATION 4 INTERCORPORATE RELATIONSHIPS 4 BUSINESS 4 OVERVIEW 4 HIGHLIGHTS 5 OUR STRATEGY 7 OUR PIPELINE 8 INTELLECTUAL |
|
| February 23, 2022 |
Management’s Discussion and Analysis of the Registrant for the year ended December 31, 2021 EX-99.3 4 blu-20211231xex99d3.htm EX-99.3 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS This Management’s Discussion and Analysis (“MD&A”) provides a review of BELLUS Health Inc.’s operations and financial performance for the years ended December 31, 2021 and 2020. In this MD&A, unless the context otherwise requires, the terms “BELLUS Health”, “we”, “us”, and “our” refer to BELLUS Health Inc. |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| February 23, 2022 |
Exhibit 99.4 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 ? I, Roberto Bellini, certify that: 1. I have reviewed this annual report on Form 40-F of BELLUS Health Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| February 23, 2022 |
EX-99.5 6 blu-20211231xex99d5.htm EX-99.5 Exhibit 99.5 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ramzi Benamar, certify that: 1. I have reviewed this annual report on Form 40-F of BELLUS Health Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| February 23, 2022 |
Exhibit 99.6 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ? The undersigned, as the President and Chief Executive Officer of BELLUS Health Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2021, which accompanies this certification, fully complies with the requirements of Section 13(a) or 1 |
|
| February 14, 2022 |
BLU / Blue Chip Value Fund, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2022 |
EX-99.1 2 d275604dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Bellus Health Inc. (Title of Class of Securities) Common Shares (CUSIP Number) 07987C |
|
| February 14, 2022 |
BLU / Blue Chip Value Fund, Inc. / COMMODORE CAPITAL LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
BLU / Blue Chip Value Fund, Inc. / CITADEL ADVISORS LLC - BELLUS HEALTH INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* BELLUS Health Inc. (Name of Issuer) Common shares without par value (the ?Shares?) (Title of Class of Securities) 07987C204 (CUSIP Number) |
|
| February 14, 2022 |
BLU / Blue Chip Value Fund, Inc. / RTW INVESTMENTS, LP - BELLUS HEALTH INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BELLUS Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 14, 2022 |
EX-1 2 bellus13gfeb42022ex1.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition |
|
| February 14, 2022 |
BLU / Blue Chip Value Fund, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-blu123121a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 11, 2022 |
BLU / Blue Chip Value Fund, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 BLUSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) BELLUS HEALTH INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 07987C204 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| February 11, 2022 |
BLU / Blue Chip Value Fund, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) BELLUS Health Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 07987C204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 27, 2021 |
BLU / Blue Chip Value Fund, Inc. / CITADEL ADVISORS LLC - BELLUS HEALTH INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* BELLUS Health Inc. (Name of Issuer) Common shares without par value (Title of Class of Securities) 07987C204 (CUSIP Number) December 15, 202 |
|
| December 27, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common shares of BELLUS Health Inc., a Canada corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersi |
|
| December 22, 2021 |
BLU / Blue Chip Value Fund, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bellus Health Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) December 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| December 17, 2021 |
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States EX-99.1 2 tm2135206d5ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States LAVAL, Quebec, December 17, 2021 – BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously- |
|
| December 17, 2021 |
6-K 1 tm2135206d56k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of princ |
|
| December 15, 2021 |
6-K 1 tm2135206d46k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of princ |
|
| December 15, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States Common Shares Priced at US$8.00 per Share LAVAL, Quebec, December 14, 2021 – In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Hea |
|
| December 15, 2021 |
SUPPL 1 tm2135102-6suppl.htm SUPPL TABLE OF CONTENTS Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-261632 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. A registration statement related to these securities has been filed with the United States Securities and Exchange Commission and has been declar |
|
| December 15, 2021 |
25,000,000 Common Shares BELLUS Health Inc. UNDERWRITING AGREEMENT Exhibit 99.2 EXECUTION VERSION 25,000,000 Common Shares BELLUS Health Inc. UNDERWRITING AGREEMENT December 14, 2021 JEFFERIES LLC EVERCORE GROUP L.L.C. RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street, 35th Floor New York, New York 10055 c/o RBC CAPITAL MARKETS, LLC Br |
|
| December 14, 2021 |
As filed with the Securities and Exchange Commission on December 14, 2021 F-10 1 tm2135102-1f10.htm F-10 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 14, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BELLUS HEALTH INC. (Exact Name of Registrant as Specified In Its Charter) Not applicable (Translation of Regist |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (?Filer?): BELLUS Health Inc. B. (1) This is: x an original filing for the Filer. ? an amended filing for the Filer. (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S- T Rule |
|
| December 13, 2021 |
6-K 1 tm2135206d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of princ |
|
| December 13, 2021 |
SUPPL 1 tm2135102-3suppl.htm SUPPL TABLE OF CONTENTS Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-251329 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. A copy of this preliminary prospectus supplement has been filed with the securities regulatory authorities in each of the provinces of Canada but |
|
| December 13, 2021 |
EX-99.1 2 tm2135206d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States LAVAL, Quebec, December 13, 2021 – BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospe |
|
| December 13, 2021 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 3 tm2135206d3ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company BELLUS Health Inc. (“BELLUS Health” or the “Company”) 275 Blvd. Armand-Frappier Laval (Québec) H7V 4A7 Item 2 Date of Material Change December 13, 2021 Item 3 News Release A news release was issued on December 13, 2021, and disseminated by Business Wire, in Canada and i |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| December 13, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ? 0.005) BLU-5937 |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| December 13, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ? 0.005) BLU-5937 |
|
| December 13, 2021 |
EX-99.2 4 tm2135206d2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Phase 2b SOOTHE Trial in Refractory Chronic Cough Topline Results and P2X3 Pipeline Update DECEMBER 13 , 2021 Forward Looking Statements 2 Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward - looking statements” within the meaning of |
|
| December 6, 2021 |
EX-99.1 2 d225692dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: December 6, 20 |
|
| December 6, 2021 |
BLU / Blue Chip Value Fund, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bellus Health Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 07987C 204 (CUSIP Number) November 23, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 10, 2021 |
Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended September 30, 2021 and 2020 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended September 30, 2021 and 2020 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Co |
|
| November 10, 2021 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three and nine-month periods ended September 30, 2021. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document sh |
|
| November 10, 2021 |
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences EX-99.1 2 a52527065ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences LAVAL, Quebec—November 10, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr |
|
| November 10, 2021 |
6-K 1 a52527065.htm BELLUS HEALTH INC. FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (A |
|
| November 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 tm2132163d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended September 30, 202 |
|
| November 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.3 4 tm2132163d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended S |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| November 10, 2021 |
6-K 1 a52528231.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Addres |
|
| November 10, 2021 |
EX-99.1 2 a52528231ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights - Announced positive findings from the Phase 2b SOOTHE trial administrative interim analysis, with at least one dose of BLU-5937 meeting the threshold for a high probability of clinical e |
|
| November 1, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937 - Live webcast to be held on November 15th at 12:00 p.m. EST ? LAVAL, Quebec ? Nov. 1, 2021 ? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-sta |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| September 24, 2021 |
BLU / Blue Chip Value Fund, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BELLUS HEALTH INC. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 07987C204 (CUSIP Number) SEPTEMBER 14, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| September 23, 2021 |
EX-99.1 2 a52496133ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis Topline results from both studies are expected in December 2021 LAVAL, Queb |
|
| September 23, 2021 |
6-K 1 a52496133.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Addre |
|
| September 13, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough Interim analysis met the threshold for a high probability of clinical efficacy Data from interim analysis support accelerated planning for the Phase 3 program SOOTHE Phase 2b trial is on trac |
|
| September 13, 2021 |
6-K 1 a52490476.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Addre |
|
| September 3, 2021 |
BLU / Blue Chip Value Fund, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bellus Health Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 07987C204 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Tele |
|
| September 3, 2021 |
EX-99.1 2 ss470712ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 3 to Schedule 13D, dated September 3, 2021, with respect to the ordinary shares of Bellus Health Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each o |
|
| September 2, 2021 |
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present at the H.C. Wainwright Global Investment Conference LAVAL, Quebec?September 2, 2021? BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (?BELLUS Health? or the ?Company?), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (?RCC?) and other h |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| August 23, 2021 |
EX-99.1 2 a52480345ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021 LAVAL, Quebec – Aug 23, 2021 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmac |
|
| August 11, 2021 |
Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended June 30, 2021 and 2020 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended June 30, 2021 and 2020 (In thousands of United States dollars) Condensed Consolidated Interim Financial Statements Condensed Co |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 tm2124422d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended June 30, 2021. 2. |
|
| August 11, 2021 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three and six-month periods ended June 30, 2021. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document should b |
|
| August 11, 2021 |
EX-99.1 2 a52475632ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights - The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 - LAVAL, Quebec – Aug 11, 2021 – BELLUS Health Inc. (Nasdaq:BLU; TSX:B |
|
| August 11, 2021 |
6-K 1 a52475632.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended June 30, 2021. 2. No misrepresentations: Based |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 25, 2021 |
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference EX-99.1 2 a52434889ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference LAVAL, Quebec—May 25, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen |
|
| May 12, 2021 |
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference LAVAL, Quebec—May 12, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic coug |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 10, 2021 |
Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS This Management?s Discussion and Analysis (?MD&A?) provides a review of BELLUS Health Inc.?s operations and financial performance for the three-month period ended March 31, 2021. In this MD&A, unless the context otherwise requires, the terms ?BELLUS Health?, ?Company?, ?we?, ?us?, and ?our? refer to BELLUS Health Inc. This document should be read i |
|
| May 10, 2021 |
BELLUS Health to Present at the American Thoracic Society 2021 International Conference EX-99.1 2 a52425996ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present at the American Thoracic Society 2021 International Conference LAVAL, Quebec—May 10, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for |
|
| May 10, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 10, 2021 |
Current Report of Foreign Issuer - BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by ch |
|
| May 10, 2021 |
Current Report of Foreign Issuer - BELLUS HEALTH INC. 6-K 6-K 1 a52426802.htm BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Québec H7V 4A7 Canada (Address of |
|
| May 10, 2021 |
Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights - Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected |
|
| May 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.5 6 tm2115493d1ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Ramzi Benamar, Chief Financial Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of BELLUS Health Inc. (the “issuer”) for the interim period ended March 31, 2021. 2 |
|
| May 10, 2021 |
BELLUS HEALTH INC. (the “Company”) REPORT OF VOTING RESULTS Exhibit 99.3 BELLUS HEALTH INC. (the ?Company?) REPORT OF VOTING RESULTS Following the annual meeting of shareholders of the Company held on May 10, 2021 (the ?Meeting?), this report discloses the matters voted upon at the Meeting. Reference is made to the management information circular of the Company dated March 23, 2021 (the ?Circular?). Election of Directors On a vote by ballot, the following |
|
| May 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Roberto Bellini, President and Chief Executive Officer of BELLUS Health Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of BELLUS Health Inc. (the ?issuer?) for the interim period ended March 31, 2021. 2. No misrepresentations: Base |
|
| May 10, 2021 |
EX-99.1 2 tm2115493d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Condensed Consolidated Interim Financial Statements of (Unaudited) BELLUS HEALTH INC. Periods ended March 31, 2021 and 2020 (In thousands of United States dollars) Bellus health INC. Condensed Consolidated Interim Financial Statements (Unaudited) Periods ended March 31, 2021 and 2020 (In thousands of United States dollars) Condensed Consoli |
|
| April 13, 2021 |
BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference EX-99.1 2 a52410381ex991.htm EXHIBIT 99.1 Exhibit 99.1 BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference LAVAL, Quebec—April 13, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the |
|
| April 13, 2021 |
Current Report of Foreign Issuer - BELLUS HEALTH INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-39034 BELLUS HEALTH INC. (Name of registrant) 275 Armand-Frappier Blvd. Laval, Qu?bec H7V 4A7 Canada (Address of principal executive offices) Indicate by |
|
| April 9, 2021 |
EX-99.4 5 exhibit99-4.htm VIRTUAL GUIDE Exhibit 99.4 |
